Granules Life Sciences Receives VAI Classification following US FDA Inspection Granules India Limited today announced that its wholly owned subsidiary, Granules Life Sciences Private Limited (GLS), has concluded a recent US FDA inspection of its manufacturing facility at Shamirpet, Telangana, with an inspection classification of Voluntary Action Indicated
A United States-based subsidiary of Cipla has initiated a recall of certain batches of its generic anti-cancer medication Nilotinib Capsules following a manufacturing issue, according to the U.S. Food and Drug Administration (USFDA). The recall, issued by Cipla USA Inc., involves more than 400 cartons of
India’s rapidly growing medical technology sector is set to receive its first dedicated investment fund of ₹1,000 crore, aimed at accelerating innovation, strengthening domestic manufacturing, and supporting high-growth medtech companies across the country. The proposed fund, MedArtha Capital, recently received regulatory approval and will focus on
Bengaluru-based medical equipment startup Pulse has successfully raised $4 million in a seed funding round led by 3one4 Capital, with participation from Incubate Fund Asia, Stride Ventures, and other angel investors, including founders of logistics and agritech companies. Founded in 2025 by Anshul Sharma and Nishant
Mankind Pharma, India’s fourth-largest pharmaceutical company, has completed a large-scale, multi-year transformation of its global supply chain and strategic procurement function to strengthen access to medicines, improve supply reliability, and support disciplined, scalable growth. Delivered in collaboration with Accenture, the integrated initiative embeds digitally enabled
The latest disbursement underscores the Company’s role in strengthening India’s domestic pharmaceutical manufacturing ecosystem Venus Remedies Limited (NSE: VENUSREM, BSE: 526953), among the world’s leading fixed-dosage injectable manufacturers, has received its second incentive disbursement under the Government of India’s Production Linked Incentive (PLI) Scheme for Pharmaceuticals, representing 75 percent
Phase II WHO Pre-Qualification covers both drug substance and drug product for nOPV2 at Biological E. Biological E. has already supplied 700 million doses for global stockpile and outbreak response use Integrated WHO-qualified manufacturing strengthens supply availability for cVDPV2 outbreak control Biological E. Limited (BE) today announced a
The Centre has worked with over 20 startups and 35 industry partners; providing end-to-end support ranging from industrial design and rapid prototyping to machining, post-processing and production. Strengthening India’s journey towards self-reliance in medical device manufacturing, the Advanced Additive Manufacturing Centre of Excellence (Coe) at Andhra
Syngene International, a global contract research, development, and manufacturing organization (CRDMO), today announced the extension of its long-standing strategic collaboration with Bristol Myers Squibb through 2035. The expanded agreement broadens the scope of integrated services across the drug development lifecycle spanning discovery (chemistry, biology, drug
In a significant milestone for indigenous medical technology, India’s homegrown stroke treatment device has successfully cleared clinical trials, paving the way for wider clinical adoption and improved access to advanced neurovascular care across the country. The breakthrough underscores India’s growing capability to design, develop, and
Join 2M+ industry professionals with MedgateToday - curated insights, delivered daily.
